This document is an excerpt from the EUR-Lex website
Document 62022TA0174
Case T-174/22: Judgment of the General Court of 15 March 2023 — Novartis v EUIPO — AstraZeneca (BREZTREV) (EU trade mark — Opposition proceedings — Application for the EU word mark BREZTREV — Earlier EU word marks ONBREZ, DAYBREZ, BREZILIZER and BREEZHALER — No likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)
Case T-174/22: Judgment of the General Court of 15 March 2023 — Novartis v EUIPO — AstraZeneca (BREZTREV) (EU trade mark — Opposition proceedings — Application for the EU word mark BREZTREV — Earlier EU word marks ONBREZ, DAYBREZ, BREZILIZER and BREEZHALER — No likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)
Case T-174/22: Judgment of the General Court of 15 March 2023 — Novartis v EUIPO — AstraZeneca (BREZTREV) (EU trade mark — Opposition proceedings — Application for the EU word mark BREZTREV — Earlier EU word marks ONBREZ, DAYBREZ, BREZILIZER and BREEZHALER — No likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)
OJ C 164, 8.5.2023, p. 39–39
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 15/03/2023
- Date lodged:
- 04/04/2022
- Author:
- General Court
- Form:
- Judicial information
- Authentic language:
- English
- Type of procedure:
- Action for annulment
- Defendant:
- European Union Intellectual Property Office
- Link
- Select all documents mentioning this document
- Case affecting:
-
- Related EU case-law document 62022TJ0174
- Instruments cited in case law:
- Link
- EUROVOC descriptor:
|
8.5.2023 |
EN |
Official Journal of the European Union |
C 164/39 |
Judgment of the General Court of 15 March 2023 — Novartis v EUIPO — AstraZeneca (BREZTREV)
(Case T-174/22) (1)
(EU trade mark - Opposition proceedings - Application for the EU word mark BREZTREV - Earlier EU word marks ONBREZ, DAYBREZ, BREZILIZER and BREEZHALER - No likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)
(2023/C 164/53)
Language of the case: English
Parties
Applicant: Novartis AG (Basle, Switzerland) (represented by: A. Nordemann-Schiffel, lawyer)
Defendant: European Union Intellectual Property Office (represented by: N. Lamsters and T. Frydendahl, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: AstraZeneca AB (Södertälje, Sweden) (represented by: C. Tenkhoff and T. Herzog, lawyers)
Re:
By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 21 January 2022 (Case R 738/2021-2).
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Novartis AG to pay the costs. |
